Alumis to Present at the Jefferies Global Healthcare Investor Conference

Rhea-AI Summary

Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's President and CEO, Martin Babler, will deliver a presentation on June 4, 2025, at 3:10 p.m. ET. Interested parties can access a live webcast of the presentation through the "Investors" section of the Alumis website, under the "Events" page. The webcast recording will remain available for replay on the company's website for 90 days following the event.

News Market Reaction – ALMS

-10.49%

1 alert

-10.49% News Effect

On the day this news was published, ALMS declined 10.49%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 p.m. ET.

A live webcast will be available on the Alumis website in the "Investors" section under the “Events” page. A replay of the conference webcast will be archived on the company's website for 90 days.

About Alumis
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, the pipeline includes lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X.

Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding Alumis’ participation at upcoming conferences. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Alumis Contact Information

Teri Dahlman
Red House Communications
teri@redhousecomms.com

FAQ

When is Alumis (ALMS) presenting at the Jefferies Global Healthcare Conference 2025?

Alumis (ALMS) will present at the Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 p.m. ET.

Who will represent Alumis (ALMS) at the Jefferies Healthcare Conference 2025?

Martin Babler, President and Chief Executive Officer of Alumis, will present at the conference.

How can investors watch Alumis (ALMS) presentation at the Jefferies Conference?

Investors can watch the live webcast through the 'Investors' section under the 'Events' page on the Alumis website.

How long will Alumis (ALMS) Jefferies Conference presentation be available for replay?

The conference webcast will be archived on the company's website for 90 days.